United States - English - NLM (National Library of Medicine)

akorn - apraclonidine hydrochloride (unii: d2vw67n38h) (apraclonidine - unii:843cen85di) - apraclonidine 5 mg in 1 ml - apraclonidine ophthalmic solution, usp 0.5% as base is indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional iop reduction. patients on maximally tolerated medical therapy who are treated with apraclonidine ophthalmic solution, usp 0.5% as base to delay surgery should have frequent follow-up examinations and treatment should be discontinued if the intraocular pressure rises significantly. the addition of apraclonidine ophthalmic solution, usp 0.5% as base to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. this is because apraclonidine ophthalmic solution, usp 0.5% as base is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce iop. the iop lowering efficacy of apraclonidine ophthalmic solution, usp 0.5% as base diminishes over time in some patients.

United States - English - NLM (National Library of Medicine)

sandoz inc - apraclonidine hydrochloride (unii: d2vw67n38h) (apraclonidine - unii:843cen85di) - apraclonidine 5.75 mg in 1 ml - apraclonidine ophthalmic solution 0.5% is indicated for short-term adjunctive therapy, in patients on maximally tolerated medical therapy, who require additional iop reduction. patients on maximally tolerated medical therapy, who are treated with apraclonidine ophthalmic solution 0.5% to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the iop rises significantly. the addition of apraclonidine ophthalmic solution 0.5% to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. this is because apraclonidine ophthalmic solution 0.5% is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce iop. the iop lowering efficacy of apraclonidine ophthalmic solution 0.5% diminishes over time in some patients. this loss of effect, or tachyphylaxis, appears to be an individual occurrence

Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - apraclonidine hydrochloride (unii: d2vw67n38h) (apraclonidine - unii:843cen85di) - apraclonidine 5 mg in 1 ml - iopidine® (apraclonidine ophthalmic solution) 0.5% is indicated for short-term adjunctive therapy, in patients on maximally tolerated medical therapy, who require additional iop reduction. patients on maximally tolerated medical therapy, who are treated with iopidine® (apraclonidine ophthalmic solution) 0.5% to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the iop rises significantly. the addition of iopidine® (apraclonidine ophthalmic solution) 0.5% to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. this is because iopidine® (apraclonidine ophthalmic solution) 0.5% is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce iop. the iop lowering efficacy of iopidine® (apraclonidine ophthalmic solution) 0.5% diminishes over time in some patients. this loss of

Israel - English - Ministry of Health

novartis israel ltd - apraclonidine as hydrochloride - ophthalmic solution - apraclonidine as hydrochloride 5 mg/ml - apraclonidine - apraclonidine - short term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (iop) reduction to delay laser treatment or glaucoma surgery.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - apraclonidine hydrochloride (unii: d2vw67n38h) (apraclonidine - unii:843cen85di) - apraclonidine 10 mg in 1 ml - iopidine 1% ophthalmic solution is indicated to control or prevent post-surgical elevations in iop that occur in patients after argon laser trabeculoplasty, argon laser iridotomy or nd:yag posterior capsulotomy. iopidine 1% ophthalmic solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - apraclonidine hydrochloride 5.75 mg/ml equivalent to 5 mg apraclonidine - eye drops, solution - 0.5 % - active: apraclonidine hydrochloride 5.75 mg/ml equivalent to 5 mg apraclonidine excipient: benzalkonium chloride hydrochloric acid purified water sodium acetate trihydrate sodium chloride sodium hydroxide - iopidine eye drops 0.5% are indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional intraocular pressure reduction. patients on maximally tolerated medical therapy who are treated with iopidine eye drops 0.5% to delay surgery should have frequent follow up examinations and treatment should be discontinued if the intraocular pressure rises significantly.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - apraclonidine hydrochloride - eye drops, solution - 1 percent weight/volume - sympathomimetics in glaucoma therapy1); apraclonidine

Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharma limited - apraclonidine hydrochloride - eye drops, solution - sympathomimetics in glaucoma therapy1); apraclonidine

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - apraclonidine hydrochloride - eye drops, solution - 5 milligram(s)/millilitre - sympathomimetics in glaucoma therapy1); apraclonidine